The development of the next generation of Alzheimer’s disease treatments is among the most important health needs worldwide, but presents huge challenges. This meeting aims to bring together today’s worldwide leaders in the treatment of Alzheimer’s disease to discuss new results, candidate therapeutics, and methodological issues important to the development of the next generation of Alzheimer’s disease treatments. Clinical trial teams from worldwide centers will report on their efforts to identify new biomarkers of disease as well as more sensitive clinical assessment tools to identify those at risk for AD, predict progression, and assess the effectiveness of new treatments. The future of clinical trials may lie in the development of combination therapies of two or more drugs. CTAD 2014 will highlight the latest on trying to get these trials off the ground.